^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

camsirubicin (MNPR-201)

i
Other names: GPX 150, 5-imino-13-deoxy-doxorubicin HCl, MNPR-201, GPX-150, CNDO-101, GPX150
Associations
Trials
Company:
Monopar Therap
Drug class:
Topoisomerase II inhibitor
Related drugs:
Associations
Trials
7ms
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov)
P1, N=14, Terminated, Monopar Therapeutics | N=21 --> 14 | Trial completion date: Jun 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2023; lack of timely enrollment
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
Neulasta (pegfilgrastim) • camsirubicin (MNPR-201)
10ms
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov)
P1, N=21, Recruiting, Monopar Therapeutics | Phase classification: P1b --> P1 | Trial primary completion date: Jun 2023 --> Jun 2025
Phase classification • Trial primary completion date • Metastases
|
Neulasta (pegfilgrastim) • camsirubicin (MNPR-201)
2years
Pre-Clinical Evaluation of a Camsirubicin Analog Mnpr-202 in Diffuse Large B Cell Lymphoma (ASH 2022)
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of aggressive lymphoma, for which the standard-of-care treatment is rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...For example, a clear antagonistic effect on cell killing was seen between PLK1 inhibitor, volasertib, and doxorubicin, but between volasertib and MNPR-202, this antagonism was seen to a significantly lesser extent...These intracellular differences also influence drug synergies observed with the two chemotherapeutics, implying that in the context of certain combinatorial regimens, MNPR-202 may be superior to doxorubicin. Overall these findings suggest promise for further in vivo and clinical evaluation of MNPR-202 as a potentially effective yet non-cardiotoxic anthracycline derivative in lymphoma.
Preclinical
|
STING (stimulator of interferon response cGAMP interactor 1)
|
Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone • volasertib (NBL-001) • MNPR-202 • camsirubicin (MNPR-201)
over4years
Pharmacological suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. (PubMed, Cancer Discov)
In preclinical models of TNBC, a triple combination of NGI-1, camsirubicin (a non-cardiotoxic doxorubicin analog) and PD-L1 blockade was effective in reducing tumor growth. Collectively, our findings uncover a novel strategy for targeting the immunosuppressive molecule B7-H4.
Journal • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • EIF2A (Eukaryotic Translation Initiation Factor 2A)
|
doxorubicin hydrochloride • camsirubicin (MNPR-201)